Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 70 results for cerebral palsy

  1. Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

    This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.

  2. Recognition and early management of pain in children and young people with cerebral palsy:- Does use of pain assessment tools by parents or carers improve the recognition and early management of pain in children and young people with cerebral palsy in a community setting?

    Recognition and early management of pain in children and young people with cerebral palsy:- Does use of pain assessment tools by parents...

  3. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

  4. Developmental follow-up of children and young people born preterm (QS169)

    This quality standard covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It describes high-quality care in priority areas for improvement.

  5. Constipation in children and young people: diagnosis and management (CG99)

    This guideline covers diagnosing and managing constipation in children and young people up to 18. It provides strategies to support the early identification and timely, effective treatment of constipation which will help improve outcomes for patients. It does not cover constipation caused by a specific condition.

  6. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

  7. Prophylactic antibiotics for respiratory disorders:- Are prophylactic antibiotics clinically and cost effective in the management of respiratory symptoms in adults with cerebral palsy with significant respiratory comorbidity?

    cost effective in the management of respiratory symptoms in adults with cerebral palsy with significant respiratory comorbidity? Any...

  8. Detection and management of respiratory disorders in primary and community care:- Can detection and management of respiratory disorders in adults with cerebral palsy be improved in primary and community care?

    community care:- Can detection and management of respiratory disorders in adults with cerebral palsy be improved in primary and...

  9. Splinting to improve or maintain posture or function:- What is the optimum regimen for splints applied to the upper limb in adults with cerebral palsy to improve or maintain posture or function?

    optimum regimen for splints applied to the upper limb in adults with cerebral palsy to improve or maintain posture or function? Any...

  10. Augmentative and alternative communication systems:- Are augmentative and alternative communication systems clinically and cost effective in promoting  communication for adults with cerebral palsy who have communication difficulties?

    clinically and cost effective in promoting communication for adults with cerebral palsy who have communication difficulties? Any...

  11. Selective dorsal rhizotomy treatment to reduce spasticity:- What is the clinical and cost effectiveness of selective dorsal rhizotomy compared with intrathecal baclofen to reduce spasticity in adults with cerebral palsy?

    compared with intrathecal baclofen to reduce spasticity in adults with cerebral palsy? Any explanatory notes(if applicable) To find out...

  12. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)

    This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.

  13. Mollii suit for spasticity (MIB100)

    NICE has a developed medtech innovation briefing on Mollii suit for spasticity .

  14. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

  15. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.